Acadia Pharmaceuticals | ACAD - 销售成本

金融业

USD 19.25

USD 1.74B

现金及等价物

USD 956.47M

USD 28.32M

USD 1.22B

USD 361.44M

USD 50.79M

USD 37.84M

USD -1.62M

653

EPS每股收益

USD 0.18

股本和储备

USD 1.31B

USD 279.64M

债务利息支出

USD 0

USD 8.06M

USD 0

USD 3.2B

USD 31.5M

USD 270.12M

USD 37.84M

普通股股本

USD 171.09M

11.33

USD 46.47M

USD 307.96M

销售和管理费用

USD 148.57M

USD 108.67M

贸易债权人

USD 44.57M

应收帐款人

USD 166.33M

	销售成本	更改		日
Acadia Pharmaceuticals	USD 28.32M		3.52M	2026-06
ALKERMES	USD 120.7M		47.44M	2026-06
Alnylam Pharmaceuticals	USD 298.45M		87.33M	2026-06
Biogen	USD 945.1M		147.6M	2026-06
BioMarin Pharmaceutical	USD 276.29M		76.8M	2026-06
Bristol-Myers Squibb	USD 7.89B		4.03B	2026-06
Cara Therapeutics	USD 0		0	2025-03
Corcept Therapeutics	USD 4.06M		1.18M	2026-06
Cytokinetics	USD 5.59M		5.43M	2026-06
Eisai	JPY 51.09B		926M	2026-06
Eli Lilly	USD 3.27B		309M	2026-06
Incyte	USD 104.96M		457K	2026-06
J&J	USD 8.08B		80M	2026-09
Moderna	USD 93M		862M	2026-06
Neurocrine Biosciences	USD 39.4M		25.6M	2026-06
Pfizer	USD 4.09B		498M	2026-06
Prothena	USD 28.94M		11.58M	2025-09
PTC Therapeutics	USD 39.61M		23.31M	2026-03
Sarepta Therapeutics	USD 150.1M		40.64M	2026-06
Ultragenyx Pharmaceutical	USD 30M		1000K	2026-03
Vanda Pharmaceuticals	USD 198.77M		151.12M	2024-12
Vertex Pharmaceuticals	USD 489.2M		96.4M	2026-06